Jan Kowalski Email

Director Biostatistics . InDex Pharmaceuticals AB

Current Roles

Employees:
27
Revenue:
$5.4M
About
InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company's shares are traded on Nasdaq First North Growth Market Stockholm.
InDex Pharmaceuticals AB Address
Berzelius väg 13
Solna, null
InDex Pharmaceuticals AB Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.